Kahm Yeon-Jee, Jung Uhee, Kim Rae-Kwon
Department of Radiation Biology, Environmental Safety Technology Research Division, Korea Atomic Energy Research Institute, Yuseong-Gu, Daejeon 34057, Republic of Korea.
Department of Radiation Life Science, University of Science and Technology, Yuseong-Gu, Daejeon 34057, Republic of Korea.
Biomedicines. 2023 May 17;11(5):1462. doi: 10.3390/biomedicines11051462.
CTNNAL1 is a protein known to be involved in cell-cell adhesion and cell adhesion. Alterations in the expression or function of CTNNAL1 have been reported to contribute to the development and progression of various types of cancer. In breast cancer, CTNNAL1 has been reported as a cancer suppressor gene, and in melanoma and lung cancer, it has been reported as a cancer driver gene. However, due to a lack of research, its function remains unclear. In this study, it is shown that CTNNAL1 regulates cancer stem cells (CSCs) in lung cancer and glioblastoma and modulates their migration and invasion abilities. CSCs are known to play an important role in the malignant transformation of cancer. They have the ability to resist chemotherapeutic drugs and irradiation, which is a known obstacle to cancer treatment. We found that CTNNAL1 regulates the ability to resist irradiation. In addition, we observed that CTNNAL1 regulates the ability of cells to migrate and invade, a key feature of the epithelial to mesenchymal transition phenomenon associated with cancer metastasis. CTNNAL1 was also involved in the secretion of C-C motif chemokine ligand 2 (CCL2), one of the chemokines. CCL2 plays a role in the recruitment of immune cells to the tumor microenvironment, but in cancer, it is known to influence malignancy and metastasis. CTNNAL1 may be a novel target for treating lung CSCs and glioma stem cells and may be used as a marker of malignancy.
CTNNAL1是一种已知参与细胞间黏附和细胞黏附的蛋白质。据报道,CTNNAL1表达或功能的改变会促进各类癌症的发生和发展。在乳腺癌中,CTNNAL1被报道为一种抑癌基因,而在黑色素瘤和肺癌中,它被报道为一种致癌驱动基因。然而,由于研究不足,其功能仍不清楚。在本研究中,结果表明CTNNAL1在肺癌和胶质母细胞瘤中调节癌症干细胞(CSCs),并调节它们的迁移和侵袭能力。已知CSCs在癌症的恶性转化中起重要作用。它们具有抵抗化疗药物和辐射的能力,这是癌症治疗中一个已知的障碍。我们发现CTNNAL1调节抵抗辐射的能力。此外,我们观察到CTNNAL1调节细胞迁移和侵袭的能力,这是与癌症转移相关的上皮-间质转化现象的一个关键特征。CTNNAL1还参与了趋化因子之一C-C基序趋化因子配体2(CCL2)的分泌。CCL2在免疫细胞向肿瘤微环境的募集中起作用,但在癌症中,已知它会影响恶性肿瘤和转移。CTNNAL1可能是治疗肺CSCs和胶质瘤干细胞的一个新靶点,并且可能用作恶性肿瘤的标志物。